| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 20% YoY increase to 384 Cr total revenue. |
|---|---|
| Margins | EBITDA margin at 17%; 180 bps improvement QoQ. |
| Demand visibility | Strong momentum in base business supported by new pipeline. |
| Management confidence | Balanced; optimistic on base business, cautious on Ibuprofen headwinds. |
Growth
Revenue grew 20% YoY to 384 Cr, driven by strong 24% base business growth.
Outlook
Management targeting 10% base business growth and becoming net-debt-free by FY29.
Risks
Ibuprofen remains loss-making with -12% margins; West Asia crisis creates supply chain vulnerability.
Last quarter's promises, checked
Delivered
- Debt reduction of 158 Cr → delivered 135 Cr + 113 Cr rights (= BEAT)
- Base business EBITDA margin 25% → delivered 26% (= BEAT)
- Q4 revenue momentum → delivered 20% YoY growth to 384 Cr (= BEAT)
Partly delivered
- Targeting debt-free by FY29 → reduced debt to ~503 Cr (= PARTIAL)
Missed
- Ibuprofen strategic options in 2 quarters → remains loss-making/unresolved (= MISS)
Earnings Call Transcript filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹691.70
- Market cap
- ₹3,324 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- -2052.0×Sector 47.4×
- Promoter holding
- 41.93%-0.07% QoQ
- FII holding
- 11.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences is notifying physical shareholders to update their PAN, KYC, and nomination details per SEBI circulars. This is a routine regulatory compliance intimation.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited held its Ninth Annual General Meeting on September 18, 2026. Shareholders transacted business, including approving related party transactions.
Solara Active Pharma Sciences Legal & Regulatory
Solara Active Pharma Sciences Limited received a rectification order dropping an earlier income tax demand of Rs. 161.92 Crore. The demand was reduced to nil.
- Value
- ₹161.9 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Limited has filed its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26. This is a periodic regulatory compliance disclosure.
Solara Active Pharma Sciences Annual General Meeting
Solara Active Pharma Sciences Limited has issued the notice for its Ninth Annual General Meeting, scheduled to be held on September 18, 2026.
Solara Active Pharma Sciences Capital Structure Change
Solara Active Pharma Sciences approved the conversion of 2,79,582 partly paid-up rights shares into fully paid-up equity. The conversion followed receipt of pending first and final call monies.
- Value
- ₹3.89 Cr